Bio-Path Holdings, Inc. (NASDAQ: BPTH) was founded in 2007 and is headquartered in Bellaire, Texas, USA. It has 9 full-time employees. It is an American clinical and preclinical oncology professional RNAi nanoparticle drug development company.
Bio-Path Holdings, Inc. (BPTH):
The product developed by Bio-Path Holdings is based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, a deoxyribonucleic acid (DNA) backbone modification designed to protect DNA from damage.
Bio-Path Holdings’ main drug candidate is prexigebersen, which is in phase II clinical trials for the treatment of acute myeloid leukemia and chronic myeloid leukemia; preclinical studies of solid tumors include breast and ovarian cancer.
Bio-Path Holdings is also developing liposome Bcl2 for the treatment of lymphoma; and liposome Stat3, which are in the preclinical stage of pancreatic cancer treatment.
The license agreement between Bio-Path and the University of Texas on the antisense nucleic acid delivery technology platform includes two single nucleic acid drug products.
